CompletedPhase 3NCT00569582

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Studying OBSOLETE: Cushing syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Corcept Therapeutics
Principal Investigator
Coleman Gross
Corcept Therapeutics
Intervention
mifepristone(drug)
Enrollment
50 enrolled
Eligibility
18 years · All sexes
Timeline
2007

Study locations (17)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00569582 on ClinicalTrials.gov

Other trials for OBSOLETE: Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Cushing syndrome

← Back to all trials